PolyPid Ltd. (PYPD) Stock

Healthcare · Biotechnology · Member of Other US Stocks

PolyPid Ltd. (PYPD) closed at USD 4.83 on 2026-10-14, a change of +30.2 % over the past year, with a market capitalization of USD 99.53M.

PolyPid Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

PolyPid Ltd. key figures

Previous close

USD 4.83 (2026-10-14)

1-year change

+30.2 %

Market cap

USD 99.53M

Enterprise value

USD 94.54M

P/E ratio (trailing)

-3.40

P/E ratio (forward)

-3.99

EPS (trailing)

-1.44

EPS (forward)

-1.23

PEG ratio

n/a

Price to book

18.49

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.37

Employees

69

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About PolyPid Ltd.

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for PolyPid Ltd. and compare it with other stocks.